Success Metrics

Clinical Success Rate
68.4%

Based on 13 completed trials

Completion Rate
68%(13/19)
Active Trials
0(0%)
Results Posted
15%(2 trials)
Terminated
6(26%)

Phase Distribution

Ph phase_2
14
61%
Ph phase_1
9
39%

Phase Distribution

9

Early Stage

14

Mid Stage

0

Late Stage

Phase Distribution23 total trials
Phase 1Safety & dosage
9(39.1%)
Phase 2Efficacy & side effects
14(60.9%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

65.0%

13 of 20 finished

Non-Completion Rate

35.0%

7 ended early

Currently Active

0

trials recruiting

Total Trials

23

all time

Status Distribution
Completed(13)
Terminated(7)
Other(3)

Detailed Status

Completed13
Terminated6
unknown3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
23
Active
0
Success Rate
68.4%
Most Advanced
Phase 2

Trials by Phase

Phase 19 (39.1%)
Phase 214 (60.9%)

Trials by Status

unknown313%
withdrawn14%
terminated626%
completed1357%

Recent Activity

Clinical Trials (23)

Showing 20 of 23 trialsScroll for more
NCT00019097Phase 2

Vaccine Therapy in Treating Patients With Multiple Myeloma

Completed
NCT00006478Phase 2

Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's Lymphoma

Terminated
NCT00085436Phase 2

DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC

Completed
NCT00003715Phase 2

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

Terminated
NCT00020462Phase 1

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma

Completed
NCT00085488Phase 1

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Completed
NCT01339663Phase 1

Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma

Completed
NCT00469820Phase 1

Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant

Terminated
NCT00436930Phase 2

Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma

Completed
NCT00093522Phase 2

Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer

Unknown
NCT00003185Phase 2

Biological Therapy in Treating Patients With Glioblastoma Multiforme

Completed
NCT00126685Phase 1

Vaccine Therapy in Treating Patients With Stage IV Melanoma

Unknown
NCT00002475Phase 2

Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer

Completed
NCT00016133Phase 1

Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That Has Been Removed During Surgery

Completed
NCT00003386Phase 2

Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer

Terminated
NCT00014573Phase 2

Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer

Completed
NCT00004022Phase 2

Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma

Completed
NCT00004024Phase 2

Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma

Completed
NCT00100971Phase 1

Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia

Terminated
NCT00343447Phase 2

Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia

Withdrawn

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
23